Myelodysplastic Syndrome – Pipeline Review, H2 2012

Myelodysplastic Syndrome – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Myelodysplastic Syndrome - Pipeline Review, H2 2012', provides an overview of the Myelodysplastic Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Myelodysplastic Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome. 'Myelodysplastic Syndrome - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Myelodysplastic Syndrome.
- A review of the Myelodysplastic Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Myelodysplastic Syndrome pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Myelodysplastic Syndrome.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Myelodysplastic Syndrome pipeline depth and focus of Myelodysplastic Syndrome therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Myelodysplastic Syndrome Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Myelodysplastic Syndrome 11
Myelodysplastic Syndrome Therapeutics under Development by Companies 13
Myelodysplastic Syndrome Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 26
Comparative Analysis 26
Mid Clinical Stage Products 27
Comparative Analysis 27
Early Clinical Stage Products 28
Comparative Analysis 28
Discovery and Pre-Clinical Stage Products 29
Comparative Analysis 29
Myelodysplastic Syndrome Therapeutics – Products under Development by Companies 30
Myelodysplastic Syndrome Therapeutics – Products under Investigation by Universities/Institutes 34
Companies Involved in Myelodysplastic Syndrome Therapeutics Development 63
Genzyme Corporation 63
Amgen Inc. 64
medac GmbH 65
Merck & Co., Inc. 66
Dainippon Sumitomo Pharma Co., Ltd. 67
Gamida Cell Ltd. 68
Bio-Path Holdings, Inc. 69
Millennium Pharmaceuticals, Inc. 70
Novartis AG 71
BioMarin Pharmaceutical Inc. 72
Sunesis Pharmaceuticals, Inc. 73
SuperGen, Inc. 74
Cyclacel Pharmaceuticals Inc. 75
Celgene Corporation 76
Incyte Corporation 77
4SC AG 78
MethylGene Inc 79
OXiGENE, Inc. 80
Telik, Inc. 81
TopoTarget A/S 82
Array BioPharma Inc. 83
Threshold Pharmaceuticals, Inc. 84
Synta Pharmaceuticals Corp. 85
BioAlliance Pharma SA 86
Clavis Pharma ASA 87
Cellerant Therapeutics, Inc. 88
Chroma Therapeutics Ltd. 89
BioMAS Ltd. 90
Apogenix GmbH 91
S*BIO Pte Ltd 92
Stemline Therapeutics, Inc. 93
Onconova Therapeutics, Inc 94
Fate Therapeutics, Inc. 95
Tragara Pharmaceuticals, Inc. 96
KaloBios Pharmaceuticals, Inc. 97
Targa Therapeutics Corp. 98
Myelodysplastic Syndrome – Therapeutics Assessment 99
Assessment by Monotherapy Products 99
Assessment by Combination Products 100
Assessment by Route of Administration 101
Assessment by Molecule Type 103
Drug Profiles 106
StemEx - Drug Profile 106
Aranesp - Drug Profile 108
Estybon - Drug Profile 110
Revlimid + Procrit - Drug Profile 113
Prograf + Methotrexate - Drug Profile 114
Vidaza + Allogeneic Stem Cell Transplantation - Drug Profile 115
Cyclophosphamide + Total Body Radiation - Drug Profile 117
Fludarabine + Melphalan + Allogeneic Stem Cell Transplantation - Drug Profile 118
Cyclophosphamide + Etoposide + Total Body Irradiation - Drug Profile 119
Carboplatin + Thiotepa + Cyclophosphamide + Allogeneic Stem Cell Transplantation - Drug Profile 120
Amsacrine + Asparaginase + Cytarabine + Daunorubicin + Etoposide + Methotrexate + Mitoxantrone + Hydrocortisone - Drug Profile 121
Anti-Thymocyte Globulin + Cyclophosphamide + Allogeneic Stem Cell Transplantation - Drug Profile 124
Cyclosporine + Anti-Thymocyte Globulin - Drug Profile 126
Fludarabine Phosphate - Drug Profile 127
Ondansetron - Drug Profile 128
Cyclophosphamide + Busulfan + Peripheral Blood Stem Cell Transplantation + Tacrolimus + Methotrexate - Drug Profile 129
Revlimid - Drug Profile 131
Busulfan + Fludarabine + Peripheral Blood Stem Cell Transplantation + Tacrolimus + Methotrexate - Drug Profile 133
Asparaginase + Cytarabine + Daunorubicin + Etoposide + Thioguanine - Drug Profile 135
Epoetin Alfa + Filgrastim - Drug Profile 137
Anti-Thymocyte Globulin + Cyclosporine - Drug Profile 138
ICL670 - Drug Profile 139
Cytarabine + Mitoxantrone + Etoposide - Drug Profile 140
Idarubicin + Cytarabine + Daunorubicin Hydrochloride + Dexamethasone + Etoposide + Thioguanine + Radiation Therapy - Drug Profile 142
Mitoxantrone Hydrochloride + Cytarabine + Daunorubicin Hydrochloride + Dexamethasone + Etoposide + Thioguanine + Radiation Therapy - Drug Profile 144
Busulfan + Cyclophosphamide + Melphalan + Allogeneic Hematopoietic Cell Transplantation - Drug Profile 146
Cyclophosphamide + Cyclosporine + Methotrexate + Stem Cell Transplantation + Radiation Therapy - Drug Profile 148
Busulfan + Radiation Therapy + Stem Cell Transplantation - Drug Profile 150
bone marrow transplantation + T cell-depleted bone marrow transplantation - Drug Profile 152
bone marrow transplantation + T cell-depleted bone marrow transplantation - Drug Profile 153
Alemtuzumab + Arsenic Trioxide + Azacitidine + Busulfan + Clofarabine + Cytarabine + Daunorubicin Hydrochloride + Fludarabine Phosphate + Gemtuzumab Ozogamicin + Melphalan + Tipifarnib + Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile 154
Cytarabine + Daunorubicin + Etoposide + Hydroxyurea + Idarubicin + Mitoxantrone + Thioguanine + Tretinoin + Valspodar - Drug Profile 157
Cytarabine + Daunorubicin + Dexamethasone + Etoposide + Idarubicin + Mitoxantrone + Thioguanine - Drug Profile 161
Cyclophosphamide + Radiation Therapy + Allogeneic Stem Cell Transplantation - Drug Profile 164
Cyclophosphamide + Cyclosporine + Methotrexate + G-CSF + Radiation Therapy - Drug Profile 166
Busulfan + Fludarabine + Radiation Therapy - Drug Profile 168
Myelodysplastic Syndrome Therapeutics – Drug Profile Updates 169
Myelodysplastic Syndrome Therapeutics – Discontinued Products 176
Myelodysplastic Syndrome Therapeutics - Dormant Products 183
Myelodysplastic Syndrome – Product Development Milestones 203
Featured News & Press Releases 203
Appendix 212
Methodology 212
Coverage 212
Secondary Research 212
Primary Research 212
Expert Panel Validation 212
Contact Us 213
Disclaimer 213

List of Tables
Number of Products Under Development for Myelodysplastic Syndrome, H2 2012 14
Products under Development for Myelodysplastic Syndrome – Comparative Analysis, H2 2012 15
Number of Products under Development by Companies, H2 2012 17
Number of Products under Development by Companies, H2 2012 (Contd..1) 18
Number of Products under Development by Companies, H2 2012 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H2 2012 21
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 22
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 23
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 24
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 25
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 26
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 27
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 28
Comparative Analysis by Late Stage Development, H2 2012 29
Comparative Analysis by Mid Clinical Stage Development, H2 2012 30
Comparative Analysis by Early Clinical Stage Development, H2 2012 31
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 32
Products under Development by Companies, H2 2012 33
Products under Development by Companies, H2 2012 (Contd..1) 34
Products under Development by Companies, H2 2012 (Contd..2) 35
Products under Development by Companies, H2 2012 (Contd..3) 36
Products under Investigation by Universities/Institutes, H2 2012 37
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 38
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 39
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 40
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 41
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 42
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 43
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 44
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 45
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 46
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 47
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 48
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 49
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 50
Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 51
Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 53
Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 54
Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 56
Products under Investigation by Universities/Institutes, H2 2012 (Contd..18) 57
Products under Investigation by Universities/Institutes, H2 2012 (Contd..19) 58
Products under Investigation by Universities/Institutes, H2 2012 (Contd..20) 59
Products under Investigation by Universities/Institutes, H2 2012 (Contd..21) 60
Products under Investigation by Universities/Institutes, H2 2012 (Contd..22) 61
Products under Investigation by Universities/Institutes, H2 2012 (Contd..23) 62
Products under Investigation by Universities/Institutes, H2 2012 (Contd..24) 63
Products under Investigation by Universities/Institutes, H2 2012 (Contd..25) 64
Genzyme Corporation, H2 2012 65
Amgen Inc., H2 2012 66
medac GmbH, H2 2012 67
Merck & Co., Inc., H2 2012 68
Dainippon Sumitomo Pharma Co., Ltd., H2 2012 69
Gamida Cell Ltd., H2 2012 70
Bio-Path Holdings, Inc., H2 2012 71
Millennium Pharmaceuticals, Inc., H2 2012 72
Novartis AG, H2 2012 73
BioMarin Pharmaceutical Inc., H2 2012 74
Sunesis Pharmaceuticals, Inc., H2 2012 75
SuperGen, Inc., H2 2012 76
Cyclacel Pharmaceuticals Inc., H2 2012 77
Celgene Corporation, H2 2012 78
Incyte Corporation, H2 2012 79
4SC AG, H2 2012 80
MethylGene Inc, H2 2012 81
OXiGENE, Inc., H2 2012 82
Telik, Inc., H2 2012 83
TopoTarget A/S, H2 2012 84
Array BioPharma Inc., H2 2012 85
Threshold Pharmaceuticals, Inc., H2 2012 86
Synta Pharmaceuticals Corp., H2 2012 87
BioAlliance Pharma SA, H2 2012 88
Clavis Pharma ASA, H2 2012 89
Cellerant Therapeutics, Inc., H2 2012 90
Chroma Therapeutics Ltd., H2 2012 91
BioMAS Ltd., H2 2012 92
Apogenix GmbH, H2 2012 93
S*BIO Pte Ltd, H2 2012 94
Stemline Therapeutics, Inc., H2 2012 95
Onconova Therapeutics, Inc, H2 2012 96
Fate Therapeutics, Inc., H2 2012 97
Tragara Pharmaceuticals, Inc., H2 2012 98
KaloBios Pharmaceuticals, Inc., H2 2012 99
Targa Therapeutics Corp., H2 2012 100
Assessment by Monotherapy Products, H2 2012 101
Assessment by Combination Products, H2 2012 102
Assessment by Stage and Route of Administration, H2 2012 104
Assessment by Stage and Molecule Type, H2 2012 107
Myelodysplastic Syndrome Therapeutics – Drug Profile Updates 170
Myelodysplastic Syndrome Therapeutics – Discontinued Products 177
Myelodysplastic Syndrome Therapeutics – Discontinued Products (Contd..1) 178
Myelodysplastic Syndrome Therapeutics – Discontinued Products (Contd..2) 179
Myelodysplastic Syndrome Therapeutics – Discontinued Products (Contd..3) 180
Myelodysplastic Syndrome Therapeutics – Discontinued Products (Contd..4) 181
Myelodysplastic Syndrome Therapeutics – Discontinued Products (Contd..5) 182
Myelodysplastic Syndrome Therapeutics – Discontinued Products (Contd..6) 183
Myelodysplastic Syndrome Therapeutics – Dormant Products 184
Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..1) 186
Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..2) 187
Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..3) 188
Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..4) 189
Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..5) 190
Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..6) 191
Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..7) 192
Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..8) 193
Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..9) 194
Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..10) 195
Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..11) 196
Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..12) 197
Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..13) 198
Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..14) 199
Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..15) 200
Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..16) 201
Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..17) 202
Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..18) 203

List of Figures
Number of Products under Development for Myelodysplastic Syndrome, H2 2012 14
Products under Development for Myelodysplastic Syndrome – Comparative Analysis, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 20
Late Stage Products, H2 2012 29
Mid Clinical Stage Products, H2 2012 30
Early Clinical Stage Products, H2 2012 31
Discovery and Pre-Clinical Stage Products, H2 2012 32
Assessment by Monotherapy Products, H2 2012 101
Assessment by Combination Products, H2 2012 102
Assessment by Route of Administration, H2 2012 103
Assessment by Stage and Route of Administration, H2 2012 104
Assessment by Molecule Type, H2 2012 105
Assessment by Stage and Molecule Type, H2 2012 106